The latest biotech news

News and Trends 3 Oct 2016

Researchers Find New Weak Spots to Develop an HIV Cure

Last week we published a thorough review on current approaches for an HIV cure, which may be available as soon as 2020. Academia has come up with two additional strategies that could make a huge difference in the study of HIV. HIV affects 36.7 million people in the world and caused 1.1 million deaths last year. Plenty of resources […]

October 3, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Oct 2016

Ask the Biotech Recruiter: The Top 10 Pitfalls in International Recruitments

Are you recruiting talent for the top levels of your company? Ask the biotech recruiter! It doesn’t matter if you’re a small-time biotech or a big-time pharma – it’s a tough process. Pact & Partners, a leading international headhunting firm, has your back with this advice on the most common mistakes and how to avoid […]

October 3, 2016 - 9 minutesmins - By External Contributor

News and Trends 1 Oct 2016

This Belgian Bioartist is deconstructing Chicken Evolution

Koen Vanmechelen is an artist that works in the intersection of art and research. His art focuses on exploring biocultural diversity… using chickens! Koen Vanmechelen‘s core artistic work is the Cosmopolitan Chicken Project (CCP), in which the artist cross-breeds chickens from all around the world. The aim: to create the ultimate chicken that will combine genes from […]

October 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 09 29 at 4.53.52 PM e1475160985987

News and Trends 30 Sep 2016

Tailored Cancer Vaccines? NousCom is working on it!

We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines. City: Basel, Switzerland Founded: 2015 Employees: unknown Financial Data: €12M raised in series A Mission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […]

September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Interview: This Biotech Could Have the First HIV Cure on the Market

InnaVirVax is one of the most advanced companies in the race to develop an HIV cure. At the SACHS Conference in Basel, we had the opportunity to pick the brain of the CEO, Joël Crouzet, about his company’s progress. Last week, we reviewed progress in biotech towards an HIV cure, which could hit the market […]

September 29, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 29 Sep 2016

Titans in Gene Therapy and TCRs make a Massive Deal

Medigene has licensed a few candidates from its TCR platform to one of the Boston ‘it’ biotechs in a deal totaling around €1B. By partnering with bluebird bio, Medigene is reestablishing itself as a leader in immuno-oncology. Founded over 20 years ago, Medigene has risen to the top of the European biotech scene with a […]

September 29, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […]

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Sep 2016

Biotech is one of the biggest Employers in Europe

As part of the European Biotech Week, EuropaBio shared yesterday a study revealing that Industrial Biotech has created 486,000 full-time jobs and contributes €31.6B to the EU. This new data emphasizes the huge role that Biotech plays on the continent’s economy. The biotech industry was in the spotlight this week at the European Parliament, where the report was presented, and it […]

September 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Sep 2016

Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology

Giants like BMS and GSK have been throwing all the money they can at developing immuno-oncological treatments. In twin deals, four smaller companies are forging new paths to cure cancer with the human immune response. A pair of agreements among immuno-oncology biotechs have been made in attempts to outflank big pharma competition. In Scandinavia, Orion will fund […]

September 28, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 28 Sep 2016

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

For our first interview at the SACHS Conference in Basel yesterday, I met with François Conquet, founder and CEO of Prexton Therapeutics. His company’s treatment for Parkinson’s Disease just passed Phase I with flying colors. Prexton Therapeutics, based in Switzerland, has been focused on discovering new small molecules to treat Parkinson’s, and one of them, an mGluR4 positive […]

September 28, 2016 - 1 minutemin - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Researchers Find New Weak Spots to Develop an HIV Cure

Ask the Biotech Recruiter: The Top 10 Pitfalls in International Recruitments

This Belgian Bioartist is deconstructing Chicken Evolution

Tailored Cancer Vaccines? NousCom is working on it!

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Interview: This Biotech Could Have the First HIV Cure on the Market

Titans in Gene Therapy and TCRs make a Massive Deal

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

Biotech is one of the biggest Employers in Europe

Little Biotechs manoeuvre to outfox Big Pharma in Immuno-Oncology

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!